Key result
Intracoronary bone marrow cell transplantation reduces infarct size at 3 months versus standard therapy alone.
Why the study?
Experimental data suggest that bone marrow-derived cells may contribute to healing after myocardial infarction, but clinical evidence was needed.
Does intracoronary transplantation of autologous mononuclear bone marrow cells improve infarct size and cardiac function in patients with acute myocardial infarction?
Comparison
Intracoronary transplantation of autologous mononuclear bone marrow cells plus standard therapy vs standard therapy alone
Design
Non-randomized cohort study
Follow-up
3 months
Authors
Loading...
May reduce infarct size post-MI; leaves open efficacy and safety in randomized trials.
Does intracoronary transplantation of autologous mononuclear bone marrow cells improve infarct size and cardiac function in patients with acute myocardial infarction?
p-value: p=0.04
Intracoronary transplantation of autologous mononuclear bone marrow cells after acute MI is safe and significantly reduces infarct size while improving cardiac function at 3 months.
Strauer et al. (2002) studied acute myocardial infarction (n=20). Intracoronary transplantation of autologous mononuclear bone marrow cells vs. Standard therapy alone was evaluated on Infarct region size determined by left ventriculography (p=0.04). Intracoronary transplantation of autologous mononuclear bone marrow cells significantly reduced the infarct region compared with standard therapy alone at 3 months (P=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: